All In Biotech

Drug Trial Radar · NCT02475317

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

A Randomized, Blinded, Placebo-controlled, Phase 1 Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adult Subjects, as Assessed by Fecal Bile Acid Excretion

Last checked: Nov 19, 2026Latest source record: Apr 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

84

Actual

Start

Jun 1, 2015

Primary completion

Dec 1, 2015

Study completion Dec 1, 2015

Sponsor

Lead sponsor
Mirum Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jun 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the relative potency of multiple oral doses of LUM001 and SHP626 administered for 7 days as assessed by fecal bile acid excretion in overweight and obese adult subjects. This study is designed to address the relative potency question for the first time in the same.

Conditions

  • Healthy Volunteers

Interventions

  • PlaceboDrug

    Participants will receive placebo matched to maralixibat/volixibat orally for 7 days.

  • MaralixibatDrug

    Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.

  • VolixibatDrug

    Participants will receive volixibat in 10 mg and 20 mg doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline of Fecal Bile Acid Excretion After Dosing (Day 6 and Day 7)Time frame: Baseline, Day 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Orleans Center for Clinical Research

    Knoxville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.